Singapore-based corporate advisory firm Evolve Capital Advisory has acquired a 10% stake in ZICO Capital, while Indonesia’s INA has partnered with S. Korean firm SK Plasma.
Singapore’s Evolve Capital buys 10% of Malaysia’s ZICO
Evolve Capital Advisory, a Singapore-based corporate advisory service provider, has acquired a 10% stake in ZICO Capital, a professional services provider, to expand its presence in Southeast Asia.
The announcement did not provide financial details of the acquisition. Evolve Capital said the deal will expand its Malaysia footprint and strengthen its presence across Southeast Asia.
ZICO has business operations in Indonesia, Lao PDR, Malaysia (including Labuan), Myanmar, Singapore, Thailand and the Philippines.
Both firms will work together to tap into the rapidly growing M&A and capital markets landscape in Malaysia and the region. Their services include IPO advisory, fundraising, M&A, capital raising, and private equity placements.
“ZICO Capital’s deep understanding of the Malaysian market, combined with our expertise in the Singapore and regional capital markets, will enable us to deliver tailored and impactful solutions to businesses in this dynamic growth corridor,” said Evolve Capital managing partner and CEO Jerry Chua.
Indonesia’s INA ties up with S. Korean firm SK Plasma
Indonesia Investment Authority (INA) and SK Plasma, a subsidiary of South Korean conglomerate SK Group, have agreed to jointly build Indonesia’s first plasma fractionation facility to advance national healthcare resilience, according to an announcement on Friday.
Located in Karawang, West Java, this facility will be a foundation for local production of Plasma-Derived Medicinal Products (PDMPs), with a processing capacity of 600,000 litres of plasma per year.
The facility is already under construction, with operations targeted to commence by the end of 2026. In the first phase, the project will launch a toll manufacturing program with SK Plasma’s facility in South Korea by the end of this year concurrent with the construction of the local facility.
Aimed to become the largest facility in Southeast Asia, this plasma fractionation plant is designed to reduce Indonesia’s current 100% reliance on imported PDMP. The project also offers several strategic benefits, including human capital empowerment and job creation through the training of local healthcare talents to operate the plant.
